Antibodies are proteins that recognize the molecular surfaces of potentially noxious
molecules to mount an adaptive immune response or, in the case of autoimmune diseases …

Antibodies are among the most frequently used tools in basic science research and in
clinical assays, but there are no universally accepted guidelines or standardized methods …

Reverse phase protein array (RPPA) technology introduced a miniaturized “antigen-down”
or “dot-blot” immunoassay suitable for quantifying the relative, semi-quantitative or …

Constitutive Notch activation is required for the proliferation of a subgroup of T-cell acute
lymphoblastic leukemia (T-ALL). Downstream pathways that transmit pro-oncogenic signals …

Little is known about the preanalytical fluctuations of phosphoproteins during tissue
procurement for molecular profiling. This information is crucial to establish guidelines for the …

Abstract'Reverse-phase'protein lysate microarray (RPA) assays use micro-scale, cell lysate
dot blots that are printed to a substrate, followed by quantitative immunochemical protein …

The NCI-60 cancer cell line panel provides a premier model for data integration, and
systems pharmacology being the largest publicly available database of anticancer drug …

More and more antibody therapeutics are being approved every year, mainly due to their
high efficacy and antigen selectivity. However, it is still difficult to identify the antigen, and …

The ultimate goal of cancer biomarker discovery is to use individual patient-derived
biochemical information to improve patients' outcomes. A recent increase in the spectrum of …

Antibodies are widely exploited as research/diagnostic tools and therapeutics. Despite
providing exciting research opportunities, the multitude of available antibodies also offers a …